MedTrace Logo

Effects of Labetalol on Nicotine Administration in Humans - 14

NCT00000297 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine

Conditions

  • Tobacco Use Disorder

Interventions

DRUG

Labetalol

Sponsors & Collaborators

Principal Investigators

  • Dorothy Hatsukami, Ph.D. · University of Minnesota

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31
Completion
2001-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000297 on ClinicalTrials.gov